{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T07:34:43Z","timestamp":1773819283920,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000936","name":"Gordon and Betty Moore Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000936","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009827","name":"Laura and John Arnold Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ophtha.2019.11.005","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:11:59Z","timestamp":1573690319000},"page":"573-581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Prescribing Patterns and Costs Associated with Postoperative Eye Drop Use in Medicare Beneficiaries Undergoing Cataract Surgery"],"prefix":"10.1016","volume":"127","author":[{"given":"Sidra","family":"Zafar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-7677","authenticated-orcid":false,"given":"Oliver D.","family":"Schein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Srikumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Makary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fasika A.","family":"Woreta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ophtha.2019.11.005_bib1","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/jama.2018.1150","article-title":"Health care spending in the United States and other high-income countries","volume":"319","author":"Papanicolas","year":"2018","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.ophtha.2019.11.005_bib2","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1001\/jama.2017.15927","article-title":"Factors associated with increases in US health care spending, 1996\u20132013","volume":"318","author":"Dieleman","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ophtha.2019.11.005_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ophtha.2017.05.024","article-title":"Brand medications and Medicare Part D: how eye care providers\u2019 prescribing patterns influence costs","volume":"125","author":"Newman-Casey","year":"2018","journal-title":"Ophthalmology"},{"issue":"16","key":"10.1016\/j.ophtha.2019.11.005_bib5","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000002589","article-title":"Medicare Part D payments for neurologist-prescribed drugs","volume":"86","author":"De Lott","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.ophtha.2019.11.005_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ajo.2011.03.018","article-title":"A\u00a0multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery","volume":"152","author":"Donnenfeld","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2019.11.005_bib7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jcrs.2017.02.002","article-title":"Comparison of prednisolone acetate 1.0% and difluprednate ophthalmic emulsion 0.05% after cataract surgery: incidence of postoperative steroid-induced ocular hypertension","volume":"43","author":"Tijunelis","year":"2017","journal-title":"J\u00a0Cataract Refract Surg"},{"issue":"12","key":"10.1016\/j.ophtha.2019.11.005_bib8","first-page":"NC05","article-title":"To study the efficacy of difluprednate ophthalmic emulsion and prednisolone acetate ophthalmic suspension on post-operative inflammation in cataract surgery","volume":"10","author":"Garg","year":"2016","journal-title":"J\u00a0Clin Diagn Res"},{"issue":"9","key":"10.1016\/j.ophtha.2019.11.005_bib9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/eye.2016.132","article-title":"Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study","volume":"30","author":"Wilson","year":"2016","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.ophtha.2019.11.005_bib10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jcrs.2012.10.039","article-title":"Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery","volume":"39","author":"Lane","year":"2013","journal-title":"J\u00a0Cataract Refract Surg"},{"issue":"13","key":"10.1016\/j.ophtha.2019.11.005_bib11","article-title":"Comparison of loteprednol etabonate 0.5% (Lotemax) to prednisolone acetate 1% (Falcon) for inflammation treatment following cataract surgery","volume":"48","author":"Grigorian","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.ophtha.2019.11.005_bib12","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.ophtha.2015.05.014","article-title":"Topical nonsteroidal anti-inflammatory drugs and cataract surgery: a report by the American Academy of Ophthalmology","volume":"122","author":"Kim","year":"2015","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ophtha.2019.11.005_bib13","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jcrs.2007.05.015","article-title":"In\u00a0vivo pharmacokinetics and in\u00a0vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac","volume":"33","author":"Walters","year":"2007","journal-title":"J\u00a0Cataract Refract Surg"},{"issue":"4","key":"10.1016\/j.ophtha.2019.11.005_bib14","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/APO.0000000000000089","article-title":"Prospective, randomized study comparing the effect of 0.1% nepafenac and 0.4% ketorolac tromethamine on macular thickness in cataract surgery patients with low risk for cystoid macular edema","volume":"4","author":"Ramakrishnan","year":"2015","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"1","key":"10.1016\/j.ophtha.2019.11.005_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ajo.2007.02.034","article-title":"Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (Acular LS) and nepafenac 0.1% (Nevanac) in patients undergoing phacoemulsification","volume":"144","author":"Bucci","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2019.11.005_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173254","article-title":"Comparison of the efficacy and patients\u2019 tolerability of nepafenac and ketorolac in the treatment of ocular inflammation following cataract surgery: a meta-analysis of randomized controlled trials","volume":"12","author":"Zhao","year":"2017","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.ophtha.2019.11.005_bib17","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3349\/ymj.2015.56.6.1671","article-title":"The effects of two non-steroidal anti-inflammatory drugs, bromfenac 0.1% and ketorolac 0.45%, on cataract surgery","volume":"56","author":"Jung","year":"2015","journal-title":"Yonsei Med J"},{"issue":"10","key":"10.1016\/j.ophtha.2019.11.005_bib18","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.jcrs.2015.10.061","article-title":"Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification","volume":"41","author":"Sahu","year":"2015","journal-title":"J\u00a0Cataract Refract Surg"},{"issue":"6","key":"10.1016\/j.ophtha.2019.11.005_bib19","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jcrs.2007.02.032","article-title":"Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors","volume":"33","year":"2007","journal-title":"J\u00a0Cataract Refract Surg"},{"issue":"4","key":"10.1016\/j.ophtha.2019.11.005_bib20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/aos.12684","article-title":"Antibiotic prevention of postcataract endophthalmitis: a systematic review and meta-analysis","volume":"93","author":"Kessel","year":"2015","journal-title":"Acta Ophthalmologica"},{"key":"10.1016\/j.ophtha.2019.11.005_bib21","first-page":"1","article-title":"ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions","author":"Barry","year":"2013","journal-title":"Eur Soc J Cataract Refract Surg"},{"issue":"124","key":"10.1016\/j.ophtha.2019.11.005_bib22","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2016.09.027","article-title":"Cataract in the adult eye Preferred Practice Pattern\u00ae","volume":"2","author":"Olson","year":"2017","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ophtha.2019.11.005_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ophtha.2015.12.011","article-title":"Intracameral antibiotics reduce the risk of endophthalmitis after cataract surgery: does the preponderance of the evidence mandate a global change in practice?","volume":"123","author":"Javitt","year":"2016","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ophtha.2019.11.005_bib24","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.ophtha.2009.03.014","article-title":"Cost-effectiveness analysis of intracameral cefuroxime use for prophylaxis of endophthalmitis after cataract surgery","volume":"116","author":"Sharifi","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ophtha.2019.11.005_bib25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jcrs.2018.01.029","article-title":"European multicenter trial of the prevention of cystoid macular edema after cataract surgery in nondiabetics: ESCRS PREMED study report 1","volume":"44","author":"Wielders","year":"2018","journal-title":"J\u00a0Cataract Refract Surg"},{"issue":"4","key":"10.1016\/j.ophtha.2019.11.005_bib26","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ophtha.2014.11.022","article-title":"Impact of the introduction of generic latanoprost on glaucoma medication adherence","volume":"122","author":"Stein","year":"2015","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ophtha.2019.11.005_bib27","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ophtha.2012.03.033","article-title":"Ophthalmic generics\u2014are they really the same?","volume":"119","author":"Chambers","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2019.11.005_bib28","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00061198-199710000-00011","article-title":"Ophthalmic generic drug approval process: implications for efficacy and safety","volume":"6","author":"Cantor","year":"1997","journal-title":"J\u00a0Glaucoma"},{"issue":"3","key":"10.1016\/j.ophtha.2019.11.005_bib29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bjophthalmol-2012-302245","article-title":"Generic medications in ophthalmology","volume":"97","author":"Zore","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2019.11.005_bib30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1089\/jop.2006.0070","article-title":"Comparative analysis of prednisolone acetate suspensions","volume":"23","author":"Roberts","year":"2007","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2019.11.005_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2015.11.021","article-title":"Variation in number of doses, bottle volume, and calculated yearly cost of generic and branded latanoprost for glaucoma","volume":"163","author":"Queen","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2019.11.005_bib32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/aos.13355","article-title":"The physical properties of generic latanoprost ophthalmic solutions are not identical","volume":"95","author":"Kolko","year":"2017","journal-title":"Acta Ophthalmologica"},{"issue":"14","key":"10.1016\/j.ophtha.2019.11.005_bib33","article-title":"Pharmaceutical evaluation of the quality and delivered dose of US latanoprost generics","volume":"53","author":"Brian","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.ophtha.2019.11.005_bib34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0886-3350(01)00801-X","article-title":"Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs","volume":"27","author":"Congdon","year":"2001","journal-title":"J\u00a0Cataract Refract Surg"},{"issue":"10","key":"10.1016\/j.ophtha.2019.11.005_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186060","article-title":"Influence of pharmaceutical marketing on Medicare prescriptions in the\u00a0District of Columbia","volume":"12","author":"Wood","year":"2017","journal-title":"PloS One"},{"issue":"8","key":"10.1016\/j.ophtha.2019.11.005_bib36","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamainternmed.2016.2765","article-title":"Pharmaceutical industry\u2013sponsored meals and physician prescribing patterns for Medicare beneficiaries","volume":"176","author":"DeJong","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.ophtha.2019.11.005_bib37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamainternmed.2013.1539","article-title":"Physician acquiescence to patient demands for brand-name drugs: results of a national survey of physicians","volume":"173","author":"Campbell","year":"2013","journal-title":"JAMA Intern Med"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642019322444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642019322444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:08:03Z","timestamp":1758982083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642019322444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0161642019322444"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.005","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing Patterns and Costs Associated with Postoperative Eye Drop Use in Medicare Beneficiaries Undergoing Cataract Surgery","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2019.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}